Erschienen in:
01.03.2008 | Adis R&D Profile
Mepolizumab
240563, Anti-IL-5 Monoclonal Antibody — GlaxoSmithKline, Anti-Interleukin-5 Monoclonal Antibody — GlaxoSmithKline, SB 240563
Erschienen in:
Drugs in R&D
|
Ausgabe 2/2008
Einloggen, um Zugang zu erhalten
Excerpt
Mepolizumab is an anti-interleukin-5 monoclonal antibody that is in clinical trials with GlaxoSmithKline (GSK) for the treatment of severe asthma, nasal polyposis and hypereosinophilic syndrome and eosinophilic oesophagitis (the latter two indications are classed as eosinophilia in the phase table). Interleukin-5 stimulates the production, activation and maturation of eosinophils. Since mepolizumab inhibits interleukin-5 and has a long terminal half-life, treatment with mepolizumab causes a sustained reduction in the numbers of circulating eosinophils. Thus, mepolizumab may be a useful therapeutic agent for the treatment of conditions characterized by increased levels of eosinophils. …